Intramuscular interferon beta-1a (IM IFNb-1a, Avonex®), subcutaneous IFNb-1a (SC IFNb-1a, Rebif®), subcutaneous IFNb-1b (SC IFN-beta-1b, Betaferon®, Extavia®) and glatiramer acetate (GA, Copaxone®) are approved first-line disease-modifying therapies (DMT) of relapsing-remitting multiple sclerosis (RRMS). The gene discussed is IFNB1; the disease is relapsing-remitting multiple sclerosis.